|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prognosis of metastatic splenic hilum lymph node in patients with gastric cancer after total gastrectomy and splenectomy显示文摘AIM:To clarify the significance of combined resection of the spleen to dissect the No.10 lymph node(LN). METHODS:We studied 191 patients who had undergone total gastrectomy with splenectomy,excluding non-curative cases,resection of multiple gastric cancer, and those with remnant stomach cancer.Various clinico-pathological factors were evaluated for any independent contributions to No.10 LN metastasis,usingχ 2 test. Significant factors were extracted for further analysis, carried out using a logistic regression method.Furthermore,lymph node metastasis was evaluated for any independent contribution to No.10 LN metastasis,using the same methods.The cumulative survival rate was calculated using the Kaplan-Meier method.The significance of any difference between the survival curves was determined using the Cox-Mantel test,and any difference was considered significant at the 5%level. RESULTS:From the variables considered to be potentially associated with No.10 LN metastasis,age, depth,invasion of lymph vessel,N factor,the numberof lymph node metastasis,Stage,the number of sites, and location were found to differ significantly between those with metastasis(the Positive Group)and those without(the Negative Group).A logistic regression analysis showed that the localization and Stage were significant parameters for No.10 LN metastasis.There was no case located on the lesser curvature in the Posi-tive Group.The numbers of No.2,No.3,No.4sa,No. 4sb,No.4d,No.7,and No.11 LN metastasis were each found to differ significantly between the Positive Group and the Negative Group.A logistic regression analysis showed that No.4sa,No.4sb,and No.11 LN metastasis were each a significant parameter for No.10 LN metastasis.There was no significant difference in survival curves between the Positive Group and the Negative Group. CONCLUSION:Splenectomy should be performed to dissect No.10 LN for cases which have No.4sa,No. 4sb or No.11 LN metastasis.However,in cases where the tumor is located on the lesser curvature,splenectomy can be omitted. | Keishiro Aoyagi Kikuo Kouhuji Motoshi Miyagi Takuya Imaizumi Junya Kizaki Kazuo Shirouzu | 2010 | World Journal of Hepatology2010，2，2： | 26 |
| 2 | Characteristics and prognosis of synchronous multiple early gastric cancer显示文摘AIM:To assess the clinicopathologic characteristics,risk factors,and prognosis for synchronous multiple early gastric cancer(SMGC).METHODS:A total of 146 patients with SMGC and1194 patients with single gastric cancer who had undergone gastrectomy between 1989 and 2008 were retrospectively analyzed to determine their clinicopathologic characteristics and postoperative survival.Tumors were classified into groups on the basis of location and histology.Smoking habits were evaluated using the Brinkman index.Clinical and pathological factors were compared using either Fisher’s exact test or Pearson’sχ2test.Logistic regression analysis was performed to identify independent risk factors.Survival rate was calculated using the Kaplan-Meier method.RESULTS:SMGCs accounted for 10.9%of gastric cancer cases and occurred predominantly in elderly male patients with a family history of gastric cancer who were both smokers and drinkers.These tumors were typically macroscopically elevated and histologically differentiated.There were no significant differences between SMGC and single gastric cancer patients with respect to tumor location,tumor size,lymph node metastasis,the number of metastatic lymph nodes,venous invasion,or tumor stage(P=0.052,P=0.347,P=0.595,P=0.805,P=0.559,and P=0.408,respectively).Further,there was no significant difference in postoperative survival between the patient groups(P=0.200).Of the 146SMGC patients,a single patient had remnant cancer.CONCLUSION:A careful preoperative endoscopy is necessary for patients who are at high risk of SMGC,and minimally invasive treatment may be indicated in some cases. | Taro Isobe Kousuke Hashimoto Junya Kizaki Naotaka Murakami Keishiro Aoyagi Kikuo Koufuji Yoshito Akagi Kazuo Shirouzu | 2013 | World Journal of Gastroenterology2013，19，41： | 17 |
| 3 | Molecular targeting therapy using bevacizumab for peritoneal metastasis from gastric cancer显示文摘AIM: To clarify the significance of vascular endothelial growth factor(VEGF) in peritoneal metastasis from gastric cancer, using the gastric cancer cell line MKN-45 compared with the high potential peritoneal dissemination gastric cancer cell line MKN-45 P. METHODS: The supernatant of culture medium of MKN-45 cells or MKN-45 P cells was collected and the concentrations were measured of various cytokines, matrix metalloproteinases, growth factor and angiogenic factors, including VEGF. We performed an initial pilot study to explore whether bevacizumab, a humanized monoclonal antibody against VEGF, had any suppressive effect on the peritoneal dissemination from gastric cancer in an experimental nude mouse modelof peritoneal metastasis. RESULTS: The concentrations of interleukin-6(IL-6), IL-8, VEGF and matrix metalloproteinase-2 protein in the culture supernatant were each significantly higher than each of those for MKN-45. In the in vivo study, the volume of ascites and the mitotic index were significantly lower in the therapy group than in the nontherapy group. The survival curve of the therapy group was significantly higher than that of the non-therapy group. These results suggested that VEGF was correlated with peritoneal metastasis from gastric cancer. CONCLUSION: Findings suggested that bevacizumab for inhibiting VEGF could suppress peritoneal dissemination from gastric cancer. | Keishiro Aoyagi Kikuo Kouhuji Motoshi Miyagi Junya Kizaki Taro Isobe Kousuke Hashimoto Kazuo Shirouzu | 2013 | World Journal of Critical Care Medicine2013，2，4： | 12 |
| 4 | Molecular targeting to treat gastric cancer显示文摘Trastuzumab that targets human epidermal growth factor receptor 2(HER2) protein is the only approved molecular targeting agent for treating gastric cancer in Japan and the outcomes have been favorable. However,trastuzumab is effective for only 10% to 20% of the population with gastric cancer that expresses HER2 protein. Molecular targeting therapy with bevacizumab against vascular endothelial growth factors(VEGF) and with cetuximab and panitumumab against the epidermal growth factors pathway that have been approved for treating colorectal cancer are not considered effective for treating gastric cancer according to several clinical trials. However,ramucirumab that targets VEGF receptor-2 prolonged overall survival in a large phase Ⅲ clinical trial and it might be an effective molecular targeting therapy for gastric cancer. The significance of molecular targeting therapy for gastric cancer remains controversial. A large-scale randomized clinical trial of novel molecular targeting agents with which to treat gastric cancer is needed. | Keishiro Aoyagi Kikuo Kouhuji Junya Kizaki Taro Isobe Kousuke Hashimoto Kazuo Shirouzu | 2014 | World Journal of Gastroenterology2014，20，38： | 5 |
| 5 | Clinical benefit of surgery for stage IV colorectal cancer with synchronous peritoneal metastasis显示文摘 | Hirotoshi Kobayashi Kenjiro Kotake Kimihiko Funahashi Kazuo Hase Koichi Hirata Tsuneo Iiai Shingo Kameoka Yukihide Kanemitsu Koutarou Maeda Akihiko Murata Masayuki Ohue Kazuo Shirouzu Keiichi Takahashi Toshiaki Watanabe Hideaki Yano Toshimasa Yatsuoka Yoj | 2014 | Journal of Gastroenterology2014，，4： | 2 |
| 6 | Optimum Treatment Strategy for Superficial Esophageal Cancer: Endoscopic Mucosal Resection versus Radical Esophagectomy显示文摘 | Hiromasa Fujita Susumu Sueyoshi Hideaki Yamana Koji Shinozaki Uhi Toh Yuichi Tanaka Takashi Mine Masahiro Kubota Kazuo Shirouzu Atsushi Toyonaga Hiroshi Harada Sigeki Ban Masahide Watanabe Yukihiko Toda Emi Tabuchi Naofumi Hayabuchi Hiroki Inutsuka | 2001 | World Journal of Surgery2001，，4： | 2 |
| 7 | Indication and Benefit of Pelvic Sidewall Dissection for Rectal Cancer显示文摘 | Kenichi Sugihara M.D. Hirotoshi Kobayashi M.D. Tomoyuki Kato M.D. Takeo Mori M.D. Hidetaka Mochizuki M.D. Shingo Kameoka M.D. Kazuo Shirouzu M.D. Tetsuichiro Muto M.D | 2006 | Diseases of the Colon & Rectum2006，，11： | 2 |
| 8 | Characteristics and prognosis of gastric cancer in young patients显示文摘 | Taro Isobe Kousuke Hashimoto Junya Kizaki Motoshi Miyagi Keishiro Aoyagi Kikuo Koufuji Kazuo Shirouzu | 2013 | Oncology Reports2013，，1： | 2 |
| 9 | Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer显示文摘 | Kousuke Hashimoto Keishiro Aoyagi Taro Isobe Kikuo Kouhuji Kazuo Shirouzu | 2014 | Gastric Cancer2014，，1： | 2 |
| 10 | Distal spread of rectal cancer and optimal distal margin of resection for sphincter-preserving surgery显示文摘 | Shirouzu K Isomoto H Kakegawa T | 1995 | Cancer1995，76，3： | 1 |
| 11 | Relationship Between Microvessel Density and Thermographic Hot Areas in Breast Cancer显示文摘 | Toshiro Yahara Toshihiro Koga Shougo Yoshida Shino Nakagawa Hiroko Deguchi Kazuo Shirouzu | 2003 | Surgery Today2003，，4： | 1 |
| 12 | Glutamine and arginine metabolism in tumor-bearing rats receiving total parenteral nutrition显示文摘 | Shogo Yoshida Nobuya Ishibashi Toshihiro Noake Yuichirou Shirouzu Toshinori Oka Kazuo Shirouzu | 1997 | Metabolism1997，，4： | 1 |
| 13 | Distal spread of rectal cancer and optimal distal margin of resection for sphincter- preserving surgery 显示文摘 | Shirouzu K Isomoto H Kakegawa T | 1995 | Cancer1995，76，3： | 1 |
| 14 | Oncologic and functional results of total mesorectal excision and autonomic nerve-preserving operation for advanced lower rectal cancer显示文摘 | Shirouzu K Ogata Y Araki Y | | 0，，09： | 1 |
| 15 | Oncologic outcomes of intersphincteric resection without preoperative chemoradiotherapy for very low rectal cancer显示文摘 | Yoshito Akagi Kazuo Shirouzu Yutaka Ogata Tetsushi Kinugasa | 2013 | Surgical Oncology2013，，2： | 1 |
| 16 | Vascular reconstruction and complications in living donor liver transplantation in infants weighing less than 6 kilograms: The Kyoto experience显示文摘 | Yasumasa Shirouzu Mureo Kasahara Daisuke Morioka Seisuke Sakamoto Kaoru Taira Kenji Uryuhara Kohei Ogawa Yasutsugu Takada Hiroto Egawa Koichi Tanaka | 2006 | Liver Transpl2006，，8： | 1 |
| 17 | Oncologic outcomes of intersphincteric resection without preoperative chemoradiotherapy for very low rectal cancer显示文摘 | Akagi Y Shirouzu K Ogata Y | 2013 | Surg Oncol2013，22，2： | 1 |
| 18 | Intersphineteric resection in patients with very low rectal cancer: a review of the Japanese experience 显示文摘 | Saito N Moriya Y Shirouzu K | 2006 | Dis Colon Rectum2006，49，10： | 1 |
| 19 | Expression of vascular endothecial growth factor and its receptor KDR (kinase domain-containing rreceptor)/Fck-1 fetal liver kinase-1 ) as prognostic factors in human colorectal cancer显示文摘 | Harada Y Ogata Y Shirouzu K | 2001 | In J Clin Oncol2001，6，5： | 1 |
| 20 | Intersphincteric resection in patients with very low rectal cancer:,a review of the Japanese experience显示文摘 | Saito N Moriya Y Shirouzu K | 2006 | Dis Colon Rectum2006，49，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员